HealthPartners Medical Policy Updates – August 2022

Click here to view the HealthPartners Medical Policy Updates » 

August 2022 HealthPartners Medical Policy Updates: 

• Ado-trastuzumab emtansine (Kadcyla®), pertuzumab (Perjeta®), and trastuzumab (Herceptin®)
• Aflibercept (Eylea®), Brolucizumab-dbll (Beovu®), and Ranibizumab (Lucentis®)
• Autism
• Autologous chondrocyte implantation (ACI)
• Belimumab (Benlysta®)
• Belimumab (Benlysta®)
• Bimatoprost (Durysta™)
• Burosumab (Crysvita®)
• Burosumab (Crysvita®)
• Casimersen (Amondys 45™)
• Casimersen (Amondys 45™)
• Chemical Health Residential Services
• Chronic Pain
• Dental services
• Dental Services
• Dental Services- Ambulatory Hospitalization and Anesthesia for Dental Care
• Discography/Intradiscal Steroid Injections
• Duopa®
• Eptinezumab-jjmr (Vyepti™)
• Eptinezumab-jjmr (Vyepti™)
• Eyewear for children
• Filgrastim (Neupogen®, Nivestym®, Zarxio®)
• Fosdenopterin (Nulibry™)
• Gender-confirming surgery
• General approach to genetic testing
• Genetic testing for aortopathies and connective tissue disorders
• Genetic testing for cardiac disorders
• Genetic testing for epilepsy, neurodegenerative, and neuromuscular disorders
• Genetic testing for eye disorders
• Genetic testing for gastroenterologic disorders (non-cancerous)
• Genetic testing for hematologic disorders (non-cancerous)
• Genetic testing for hereditary cancer susceptibility
• Genetic testing for hereditary cancer susceptibility
• Genetic testing for hereditary hearing loss
• Genetic testing for immune disorders
• Genetic testing for kidney disorders
• Genetic testing for lung disorders
• Genetic testing for metabolic, endocrine, and mitochondrial disorders
• Genetic testing for multisystem inherited disorders, intellectual disability, and developmental delay
• Genetic testing for prenatal and preconception carrier screening
• Genetic testing for prenatal diagnosis (via amniocentesis, CVS, or PUBS) and pregnancy loss
• Genetic testing: dermatologic conditions
• Genetic testing: exome and genome sequencing for the diagnosis of genetic disorders
• Genetic testing: non-invasive prenatal screening (NIPS)
• Genetic testing: pharmacogenetics
• Genetic testing: skeletal dysplasia and rare bone disorders
• Golimumab (Simponi ARIA®)
• Ibalizumab-uiyk (Trogarzo™)
• Ibalizumab-uiyk (Trogarzo™)
• Immune Globulin Therapy
• Immune Globulin Therapy
• Inclisiran (Leqvio®)
• Infliximab (Remicade®, Inflectra®, Renflexis®)
• Inpatient
• Intensive residential treatment services (IRTS)
• Intra-articular Hyaluronan (Viscosupplementation)
• Investigational services
• Isatuximab-irfc (Sarclisa®)
• Natalizumab (Tysabri®)
• Natalizumab (Tysabri®)
• Ocrelizumab (Ocrevus)
• Ocrelizumab (Ocrevus)
• Onasemnogene abeparvovec-xioi (Zolgensma®)
• Onasemnogene abeparvovec-xioi (Zolgensma®)
• Oncology drug coverage
• Oncology drug coverage
• Oncology: algorithmic testing
• Oncology: cancer screening
• Oncology: circulating tumor DNA and circulating tumor cells (liquid biopsy)
• Oncology: cytogenetic testing
• Oncology: molecular analysis of solid tumors and hematologic malignancies
• Oncology: molecular analysis of solid tumors and hematologic malignancies
• Pegfilgrastim (Neulasta®, Fulphila™, Nyvepria™, Udenyca™, and Ziextenzo®)
• Pegfilgrastim (Neulasta®, Fulphila™, Udenyca™)
• Pegloticase (Krystexxa®)
• Pegloticase (Krystexxa®)
• Pembrolizumab (Keytruda®)
• Pembrolizumab (Keytruda®)
• Personal care assistant (PCA)
• Preimplantation genetic testing
• Preventive care services
• Ranibizumab (Susvimo™)
• Recent Food and Drug Administration (FDA) approved medications coverage policy
• Rhinoplasty & septorhinoplasty
• Rituximab (Rituxan®, Rituxan Hycela®)
• Rituximab (Rituxan®, Ruxience™, Truxima®, Rituxan Hycela®, and Riabni™)
• Romosozumab-aqqg (Evenity®)
• Romosozumab-aqqg (Evenity®)
• Sacituzumab govitecan-hziy (Trodelvy™)
• Somatostatin Analogues for Acromegaly (Sandostatin LAR®, Somatuline Depot®, Signifor LAR®, Somavert®)
• Spinal fusion, lumbar
• Spinal Lumbar Laminectomy
• Surgical treatments for lipedema and lymphedema
• Temporomandibular Disorder (TMD) Treatments
• Teprotumumab-trbw (Tepezza®)
• Third Party Payments
• Tocilizumab (Actemra®)
• Trastuzumab (Herceptin®, Herzuma®, Kanjinti™, Ogivri™, Ontruzant®, Trazimera™), and trastuzumab and hyaluronidase-oysk (Herceptin Hylecta™)
• Ustekinumab (Stelara®)
• Vedolizumab (Entyvio®)
• Wearable cardioverter defibrillator and non-wearable automatic external defibrillator
• Wearable cardioverter defibrillator and nonwearable automatic external defibrillator

Click here to view the HealthPartners Medical Policy Updates »

HealthPartners

Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.